Analyst Michael King works at BENCHMARK and is focused on the Healthcare sector with 85 price targets and ratings documented since 2013 spanning on 18 stocks. Previously, Michael King worked at HCWAINWRIGHT, JMP. Analyst's average stock valuation to be materialised ratio is 46.22% with an average time for price targets to be met of 153.5 days.
Most recent stock forecast was given on XNCR, Xencor, Inc at 31-Jan-2023.
Michael King best performing recommendations are on NTLA (INTELLIA THERAPEUTICS, INC).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS, INC) at 6/28/2021. The price target of $171 was fulfilled within 3 days with a profit of $37.57 (28.16%) receiving and performance score of 93.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential distance
Previous price target
Date
Price targets met ratio
Average potential upside
Average time for PT to be met
Performance score
Hold
143
$-86.75 (-37.76%)
145
14 days ago
2/14 (14.29%)
$-35.63 (-24.57%)
30
Buy
253
$23.25 (10.12%)
226
1 months 21 days ago
61/62 (98.39%)
$50.54 (56.72%)
592
Buy
415
$185.25 (80.63%)
3 months 4 days ago
1/4 (25%)
$110.64 (62.49%)
664
Buy
236
$6.25 (2.72%)
216
3 months 9 days ago
19/19 (100%)
$27.96 (34.44%)
266
Buy
270
$40.25 (17.52%)
273
3 months 9 days ago
5/7 (71.43%)
$23.24 (12.54%)
44
